Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
We are Simbec-Orion, who for almost five decades, have been providing clinical trial management services across a wide range of therapeutic indications and phases. The clinical research organisation with a flexible, specialist approach, we strive to become a trusted partner for our clients. Our passion as a CRO is rare diseases and oncology.
Stratagem's "Strategically Different" approach delivers: • An out-sourced, total intellectual property management solution. • An investible patent strategy and maximised value of intellectual property. • Hands-on management of the creation, maintenance, defence, commercialization, and enforcement of IP rights. • A proven strategic approach to securing freedom to commercialise and competitive advantage. Services For BioPartner Members: • Free 30-minute initial consultation for IP-related matters • IP overview training sessions for entire companies or select groups e.g. managers or inventors • Contributions towards presentations, panel discussions, and/or Q&A sessions.
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.
The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.
Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.
Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.
TheraCryf is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.
There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods.
TheraCryf exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.
Theramex is a global speciality pharmaceutical company solely committed to supporting the health needs of women through every stage of life.
Theramex have helped millions of women around the world live better lives. They continue to work on patient-focused, effective solutions that support women of all ages.
They work closely with our partners, healthcare professionals, and patients to provide women with the right solution, at the time they most need it.
The imminent expiration of patents for major pharmaceutical drugs, known as the "patent cliff," not only opens the market for lower-priced generics but also presents a prime opportunity for biotech companies to secure valuable partnerships with pharma as they seek to revitalise their portfolios.
